Mayo Clinic News Network

News Resources

Paul Scotti (@pscotti)

Activity by Paul Scotti

Paul Scotti (@pscotti) posted · Mon, Oct 20 6:00pm · View  

Trastuzumab (Herceptin) Continues to Show Life-Altering Benefit

large crowd of women in pink t shirts for breast cancer awareness


Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit 

JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.

They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.

These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 30 3:27pm · View  

Dados de estudos clínicos mundiais de dois medicamentos para câncer de mama HER2-positivo mostra que o trastuzumabe deve permanecer como o padrão de tratamento

JACKSONVILLE, Flórida 30 de setembro de 2014 — Análises em mais de 8 mil mulheres, que participaram do maior estudo mundial de dois medicamentos para o câncer de mama HER2-positivo, reforçam outras descobertas de estudos clínicos mostrando que o trastuzumabe (Herceptin) deve permanecer como o padrão de tratamento desse tipo de câncer, diz uma pesquisadora da Clínica Mayo. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 30 2:41pm · View  

Datos de un ensayo clínico realizado a nivel mundial con dos fármacos contra el cáncer de mama HER2-positivo muestran que el trastuzumab debería permanecer como tratamiento estándar

JACKSONVILLE, Florida, 30 de septiembre 2014 — Investigaciones en más de 8.000 mujeres, que participaron en el estudio más grande del mundo de dos tratamientos para el cáncer de mama HER2-positivo, refuerzan otros hallazgos de este ensayo clínico que demuestran que el fármaco trastuzumab (Herceptin) debiera seguir siendo el tratamiento estándar en este tipo de cáncer, expresa una investigadora de la Clínica Mayo. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Mon, Sep 29 10:00am · View  

Data From Worldwide Trial of Two HER2-Positive Breast Cancer Drugs Shows That Trastuzumab Should Remain as Standard of Care

JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Fri, Sep 12 1:22pm · View  

Physicians Find Liver Transplant Patients Can Avoid Costly Stay In ICU Post Surgery

JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).

In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.

MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199. Email: scotti.paul@mayo.edu

[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 2 9:00am · View  

Mayo Clinic, University of North Florida Host Tenth Annual Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship

JACKSONVILLE, Fla., Sept. 2, 2014 – Mayo Clinic and the University of North Florida are honoring Upbeat Pink ConcertNational Breast Cancer Awareness Month in October by hosting the tenth annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 10 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the university’s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.

The theme for this year’s program, “Dancing with the Survivors,” showcases a variety of dance music performed by the UNF Wind Symphony, conducted by Gordon Brock, D.M.A., and features special guest artist and multi-instrumentalist,  Bill Prince, D.M.A.

Guest speakers will include Laura Vallow, M.D., radiation oncologist at Mayo Clinic and Dianne Wagner, a local breast cancer survivor.
[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Thu, Jun 5 2:35pm · View  

Estudo ALTTO sobre terapia combinada anti HER2, no Câncer de Mama, indica que um único agente, o Trastuzumabe, permanece como o padrão ouro de tratamento

CHICAGO — No maior estudo clínico já realizado para analisar a eficácia do tratamento do câncer de mama HER2 positivo, com um ou com a combinação de dois medicamentos, os pesquisadores relataram que o uso do lapatinibe (Tykerb) não apresentou  benefício ao tratamento auxiliar padrão com trastuzumabe (Herceptin), conforme apresentado durante o  50º encontro anual da Sociedade Americana de Oncologia Clínica (ASCO — American Society of Clinical Oncology).

Resultados do estudo clínico de fase III ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study) demonstraram que ao acrescentar lapatinibe ao tratamento com trastuzimabe e quimioterapia não melhorou os resultados gerais para os pacientes (definidos como sobrevida livre da doença ou sobrevida total) e que o uso de lapatinibe aumentou de forma significativa a toxicidade do tratamento. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Thu, Jun 5 2:12pm · View  

Cáncer de mama: Estudio ALTTO sobre terapia combinada anti HER2, encuentra que agente único — el Trastuzumab — sigue siendo el mejor tratamiento estándar

CHICAGO — En el mayor estudio clínico que prueba la eficacia de un tratamiento versus dos drogas para tratar el cáncer de mama HER2-positivo, lapatinib (Tykerb ) no agregó beneficio en relación a la terapia adyuvante estándar, trastuzumab (Herceptin), según informan investigadores de la 50a reunión anual de la Sociedad Americana de Oncología Clínica (ASCO).

Los resultados del ensayo clínico de fase III, ALTTO (Estudio de Optimización de Tratamiento Adyuvante Lapatinib y/o Trastuzumab), demostraron que agregando lapatinib a trastuzumab y quimioterapia no mejoró el resultado del paciente (definido como supervivencia libre de enfermedad o supervivencia sin progresión de ésta),  y que el uso de lapatinib incrementó significativamente la toxicidad del tratamiento. [...]

Click here to view the rest of the post

Login here to comment.

Load More    

Loading information...